Importance of Ocular, Systemic and Psychosocial Factors in the Management of the Diabetic Macular Oedema Patient with Antivascular Endothelial Growth Factor Therapy

LONDON, February 7, 2017 /PRNewswire/ —
Richard Gale, Angela Carneiro, Julie de Zaeytijd, Paul Dodson, Sascha Fauser, João Figueira, Michael Larsen, Michael Kapusta, Jose M Ruiz-Moreno, Enrico Peiretti, Christian Pruente, Christoph Scholda, Reiner O Schlingemann
 
European Ophthalmic Review, 2016;10(2):117-24 DOI: https://doi.org/10.17925/EOR.2016.10.02.117

Published recently in European Ophthalmic Review, the peer-reviewed journal from touchOPHTHALMOLOGY, Richard Gale et al provide an expert overview of patient features that influence the management of patients with diabetic macular oedema (DMO). These features are grouped into three overarching themes: ocular, systemic and psychosocial. Consensus statements about the relative importance of these features, supported by the literature, were formed by a panel of retinal experts. The major drivers influencing the management of DMO with anti-vascular endothelial growth factor (anti-VEGF) therapy are undoubtedly ocular specific, in particular visual acuity and optical coherence tomography (OCT) central retinal thickness. Systemic factors, such as control of glycated haemoglobin (HbA1c), blood pressure and serum lipid estimations, have limited direct influence on DMO management although they remain important considerations to communicate to the primary diabetic physician. A greater understanding is required on how many other factors, in particular psychosocial factors, influence the care of the DMO patient.

The full peer-reviewed, open-access article is available here:
https://doi.org/10.17925/EOR.2016.10.02.117

Disclosure: Richard Gale has worked as a consultant for Novartis and Bayer. Julie de Zaeytijd has participated in advisory boards and/or consultancy for Allergan, Bayer, Novartis and Abbott, and lectured for Novartis. João Figueira has participated in advisory boards of Bayer, Allergan, Novartis, Alcon and Alimera. Nicolas Leveziel has participated in advisory boards of Bayer, Allergan and Novartis. Jose M Ruiz-Moreno has participated in advisory boards of Bayer, Allergan and Novartis.

Note to the Editor
touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the European Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from ‘data-rich’ primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
http://www.touchOPHTHALMOLOGY.com

For inquires please contact:
Nicola Cartridge – Managing Editor
+44(0)-207-193-3186
editor@touchmedicalmedia.com
Providing practical opinion to support best practice for busy healthcare professionals.

SOURCE touchOPHTHALMOLOGY